Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,030.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price upped by Bank of America from $908.00 to $1,030.00 in a report released on Monday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on the company. Sanford C. Bernstein boosted their price objective on Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a “market perform” rating in a research report on Friday, August 14th. Piper Sandler increased their price target on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a research note on Monday, October 19th. Raymond James Financial boosted their price target on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. HSBC upped their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Finally, Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $898.97.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $930.67 on Monday. The company has a quick ratio of 3.66, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average price is $800.69 and its two-hundred day moving average price is $741.11. Regeneron Pharmaceuticals has a 52-week low of $591.52 and a 52-week high of $991.73. The stock has a market capitalization of $95.82 billion, a P/E ratio of 20.38, a P/E/G ratio of 1.45 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating the consensus estimate of $16.51 by $3.56. The company had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s revenue was up 36.3% compared to the same quarter last year. During the same period in the prior year, the company earned $11.83 earnings per share. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals will post 51.64 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Christine A. Poon sold 7,830 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the sale, the director directly owned 5,219 shares of the company’s stock, valued at approximately $5,057,680.71. This trade represents a 60.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 20,789 shares of company stock worth $18,766,698. Corporate insiders own 6.97% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Orbimed Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at about $11,358,000. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $5,682,636,000. Contravisory Investment Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $6,327,000. Oxbow Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $3,342,000. Finally, Deutsche Bank AG bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $323,249,000. Institutional investors own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.